Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Home

Investor Home

As a biopharmaceutical company focused on creating cutting-edge therapies and technologies for patients with diabetes and orphan lung diseases, MannKind is on a mission to help people take control of their health. Our approved product, Afrezza® (insulin human) Inhalation Powder, is an ultra rapid-acting inhaled insulin that was approved by the U.S. FDA in June 2014 and became available by prescription in U.S. pharmacies in February 2015. Afrezza utilizes our proprietary Technosphere® Technology, an innovative, dry-powder formulation technology that allows medication to be delivered through the lungs.
investor FAQs
Show All
When was MannKind Corporation founded?

February 1991.

What is your fiscal year?

December 31

On which exchange does MannKind trade and what is the symbol?

Nasdaq: MNKD

How do I contact your Investor Relations?

To contact MannKind’s Investor Relations, please fill out the online information request form or e-mail:

Where are the MannKind headquarters?
MannKind Corporation
30930 Russell Ranch Road
Suite 300
Westlake Village, CA 91362
Phone: (818) 661-5000
Who is your transfer agent?


462 South 4th Street Suite 1600
Louisville, KY 40202
Phone: +1 877 484 5051

Data Provided by Refinitiv. Minimum 15 minutes delayed.